| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2240 |
| Trial ID | NCT04156659 |
| Disease | B-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Tisagenlecleucel|Kymriah |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Withdrawn |
| Title | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL |
| Year | 2019 |
| Country | China |
| Company sponsor | Novartis Pharmaceuticals |
| Other ID(s) | CCTL019B2210 |
| Cohort 1 | |||||||||||
|
|||||||||||